Target Validation Studies of PS48, a PDK-1 Allosteric Agonist, for the Treatment of Alzheimer’s Disease Phenotype in APP/PS1 Transgenic Mice
International Journal of Molecular Sciences · 08.04.2025 · 26 (8) · 3473
DOI: 10.3390/ijms26083473 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.04.2025. Verfasst von Henry W Querfurth und 5 weiteren Autor:innen. Beteiligte Einrichtung: Tufts Medical Center, Department of Neurology and Tufts University School of Medicine, Department of Neuroscience, 800 Washington St., and 136 Harris…. Hauptthemen laut MEDLINE: Alzheimer Disease, Presenilin-1, Pyruvate Dehydrogenase Acetyl-Transferring Kinase, Amyloid beta-Protein Precursor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bennett Foundation, National Institute of Health.
Themen: Demenz
Abstract (Originalsprache)
The Alzheimer’s disease (AD)-affected brain is known to be deficient in the utilization of glucose, its main energy substrate, and systemic diabetes is a significant risk factor for AD. In the course of biochemical and molecular investigations into this puzzling relationship, it has been shown that resistance to insulin action is a prominent feature of early stages of AD in the brain, thereby contributing to an energy failure state and a decline in synaptic function. In one AD-like cellular model, we found that β-amyloid (Aβ) accumulation inhibited insulin signaling and cell viability through an alteration of the PI3K/PDK-1/Akt signal pathway, an effect overcome by mTORC2 stimulation. A PDK-1 allosteric agonist, PS48, as well as newly synthesized analogs, were also found to reverse the metabolic defects caused by intracellular Aβ42 accumulation. In vivo, we previously showed that oral dosing of PS48 significantly improves learning and memory in APP/PS1 transgenic mice. Herein, we present evidence using unbiased immunohistological quantification and Western blot analyses demonstrating that ingested PS48 crosses into brain tissue where it targeted Akt and GSK3-β activities. Beneficial effects on neuronal number and Tau phosphorylation were found. Not unexpectedly, Aβ levels remained unchanged. These results support a path toward a future therapeutic trial of this untested strategy and agent in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tufts Medical Center, Department of Neurology and Tufts University School of Medicine, Department of Neuroscience, 800 Washington St., and 136 Harrison Ave., Boston, MA 02111, USA.
- Brigham and Women's Hospital, ARCND, 60 Fenwood Rd., Hale Bldg. for Transformative Medicine, Boston, MA 02115, USA.
- Psychogenics Inc., 215 College Rd., Paramus, NJ 07652, USA.
- Chobanian and Avedisian School of Medicine, Department of Pharmacology, Physiology and Biophysics, Boston University, 72 E. Concord St., Boston, MA 02118, USA.
- Tufts Medical Center, Department of Neurology, 800 Washington St., Boston, MA 02111, USA.
ORCID-Profile: Cynthia Lemere, Daniel Havas, Weiming Xia
Förderung
- Bennett Foundation
- National Institute of Health
Zitieren
APA
Querfurth, H. W., Lemere, C., Ciola, J., Havas, D., Xia, W., & Lee, H. K. (2025). Target Validation Studies of PS48, a PDK-1 Allosteric Agonist, for the Treatment of Alzheimer’s Disease Phenotype in APP/PS1 Transgenic Mice. International Journal of Molecular Sciences, 26(8), 3473. https://doi.org/10.3390/ijms26083473
Vancouver
Querfurth HW, Lemere C, Ciola J, Havas D, Xia W, Lee HK. Target Validation Studies of PS48, a PDK-1 Allosteric Agonist, for the Treatment of Alzheimer’s Disease Phenotype in APP/PS1 Transgenic Mice. International Journal of Molecular Sciences. 2025;26(8):3473. doi:10.3390/ijms26083473
BibTeX
@article{Querfurth2025,
author = {Querfurth, Henry W and Lemere, Cynthia and Ciola, Jason and Havas, Daniel and Xia, Weiming and Lee, Han Kyu},
title = {Target Validation Studies of PS48, a PDK-1 Allosteric Agonist, for the Treatment of Alzheimer’s Disease Phenotype in APP/PS1 Transgenic Mice},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {8},
pages = {3473},
doi = {10.3390/ijms26083473}
}
EUVIMED